Browse EFNB2

Summary
SymbolEFNB2
Nameephrin-B2
Aliases LERK5; Htk-L; HTKL; MGC126226; MGC126227; MGC126228; HTK ligand; ligand of eph-related kinase 5; eph-related ......
Chromosomal Location13q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF00812 Ephrin
Function

Cell surface transmembrane ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Binds to receptor tyrosine kinase including EPHA4, EPHA3 and EPHB4. Together with EPHB4 plays a central role in heart morphogenesis and angiogenesis through regulation of cell adhesion and cell migration. EPHB4-mediated forward signaling controls cellular repulsion and segregation from EFNB2-expressing cells. May play a role in constraining the orientation of longitudinally projecting axons. ; FUNCTION: (Microbial infection) Acts as a receptor for Hendra virus and Nipah virus.

> Gene Ontology
 
Biological Process GO:0001525 angiogenesis
GO:0001655 urogenital system development
GO:0001667 ameboidal-type cell migration
GO:0001822 kidney development
GO:0001945 lymph vessel development
GO:0002040 sprouting angiogenesis
GO:0002042 cell migration involved in sprouting angiogenesis
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0007159 leukocyte cell-cell adhesion
GO:0007409 axonogenesis
GO:0007411 axon guidance
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0010631 epithelial cell migration
GO:0010837 regulation of keratinocyte proliferation
GO:0010839 negative regulation of keratinocyte proliferation
GO:0014706 striated muscle tissue development
GO:0016202 regulation of striated muscle tissue development
GO:0019058 viral life cycle
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030260 entry into host cell
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0035051 cardiocyte differentiation
GO:0035239 tube morphogenesis
GO:0035904 aorta development
GO:0035909 aorta morphogenesis
GO:0042110 T cell activation
GO:0042692 muscle cell differentiation
GO:0043534 blood vessel endothelial cell migration
GO:0043542 endothelial cell migration
GO:0043616 keratinocyte proliferation
GO:0044409 entry into host
GO:0045785 positive regulation of cell adhesion
GO:0045844 positive regulation of striated muscle tissue development
GO:0046718 viral entry into host cell
GO:0048013 ephrin receptor signaling pathway
GO:0048514 blood vessel morphogenesis
GO:0048634 regulation of muscle organ development
GO:0048636 positive regulation of muscle organ development
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048738 cardiac muscle tissue development
GO:0048844 artery morphogenesis
GO:0048845 venous blood vessel morphogenesis
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050680 negative regulation of epithelial cell proliferation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0050920 regulation of chemotaxis
GO:0051146 striated muscle cell differentiation
GO:0051147 regulation of muscle cell differentiation
GO:0051149 positive regulation of muscle cell differentiation
GO:0051153 regulation of striated muscle cell differentiation
GO:0051155 positive regulation of striated muscle cell differentiation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051701 interaction with host
GO:0051806 entry into cell of other organism involved in symbiotic interaction
GO:0051828 entry into other organism involved in symbiotic interaction
GO:0055007 cardiac muscle cell differentiation
GO:0055024 regulation of cardiac muscle tissue development
GO:0055025 positive regulation of cardiac muscle tissue development
GO:0060537 muscle tissue development
GO:0060562 epithelial tube morphogenesis
GO:0060840 artery development
GO:0060841 venous blood vessel development
GO:0061564 axon development
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0072001 renal system development
GO:0072073 kidney epithelium development
GO:0072176 nephric duct development
GO:0072178 nephric duct morphogenesis
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0097485 neuron projection guidance
GO:1901342 regulation of vasculature development
GO:1901861 regulation of muscle tissue development
GO:1901863 positive regulation of muscle tissue development
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903847 regulation of aorta morphogenesis
GO:1903849 positive regulation of aorta morphogenesis
GO:1904018 positive regulation of vasculature development
GO:1905207 regulation of cardiocyte differentiation
GO:1905209 positive regulation of cardiocyte differentiation
GO:2000725 regulation of cardiac muscle cell differentiation
GO:2000727 positive regulation of cardiac muscle cell differentiation
Molecular Function GO:0001618 virus receptor activity
GO:0046875 ephrin receptor binding
Cellular Component GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0030055 cell-substrate junction
> KEGG and Reactome Pathway
 
KEGG hsa04360 Axon guidance
Reactome R-HSA-422475: Axon guidance
R-HSA-1266738: Developmental Biology
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928665: EPH-ephrin mediated repulsion of cells
R-HSA-3928662: EPHB-mediated forward signaling
R-HSA-3928664: Ephrin signaling
Summary
SymbolEFNB2
Nameephrin-B2
Aliases LERK5; Htk-L; HTKL; MGC126226; MGC126227; MGC126228; HTK ligand; ligand of eph-related kinase 5; eph-related ......
Chromosomal Location13q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EFNB2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolEFNB2
Nameephrin-B2
Aliases LERK5; Htk-L; HTKL; MGC126226; MGC126227; MGC126228; HTK ligand; ligand of eph-related kinase 5; eph-related ......
Chromosomal Location13q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EFNB2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEFNB2
Nameephrin-B2
Aliases LERK5; Htk-L; HTKL; MGC126226; MGC126227; MGC126228; HTK ligand; ligand of eph-related kinase 5; eph-related ......
Chromosomal Location13q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EFNB2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7720.0375
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8450.457
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7220.421
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5090.176
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6930.662
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2780.891
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2410.646
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2210.867
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2570.86
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0830.948
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8060.251
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0270.852
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EFNB2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEFNB2
Nameephrin-B2
Aliases LERK5; Htk-L; HTKL; MGC126226; MGC126227; MGC126228; HTK ligand; ligand of eph-related kinase 5; eph-related ......
Chromosomal Location13q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EFNB2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEFNB2
Nameephrin-B2
Aliases LERK5; Htk-L; HTKL; MGC126226; MGC126227; MGC126228; HTK ligand; ligand of eph-related kinase 5; eph-related ......
Chromosomal Location13q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EFNB2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EFNB2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEFNB2
Nameephrin-B2
Aliases LERK5; Htk-L; HTKL; MGC126226; MGC126227; MGC126228; HTK ligand; ligand of eph-related kinase 5; eph-related ......
Chromosomal Location13q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EFNB2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEFNB2
Nameephrin-B2
Aliases LERK5; Htk-L; HTKL; MGC126226; MGC126227; MGC126228; HTK ligand; ligand of eph-related kinase 5; eph-related ......
Chromosomal Location13q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EFNB2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEFNB2
Nameephrin-B2
Aliases LERK5; Htk-L; HTKL; MGC126226; MGC126227; MGC126228; HTK ligand; ligand of eph-related kinase 5; eph-related ......
Chromosomal Location13q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EFNB2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEFNB2
Nameephrin-B2
Aliases LERK5; Htk-L; HTKL; MGC126226; MGC126227; MGC126228; HTK ligand; ligand of eph-related kinase 5; eph-related ......
Chromosomal Location13q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EFNB2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.